California Supreme Court Rejects Novel Product Liability Theory — A Win in the Nation’s #1 Judicial Hellhole®
The California Supreme Court delivered a significant victory for pharmaceutical innovation and patient safety this week, rejecting a sweeping theory of liability that would have allowed plaintiffs to sue drug manufacturers simply for not rushing an alternative drug to market faster.
At the heart of the case was a novel legal theory: that Gilead Sciences owed a duty of care to HIV patients taking one of its drugs because it allegedly delayed commercializing a safer alternative — not because the drug they were taking was defective in any way. The plaintiffs’ bar argued that a manufacturer can be held liable even when its product works exactly as intended, simply because a different product might have been marginally better.
The Court said no.
“What today’s decision declines to do is recognize, for the first time anywhere, sweeping liability for injuries caused by a concededly nondefective drug because the manufacturer allegedly failed to make a different drug available sooner,” the Court wrote. “Imposing such liability would create substantial burdens and would risk adverse consequences for pharmaceutical innovation, public health, and patient safety.”
The ruling would have transformed every complex business and scientific decision made during drug development into a potential jury question. The Wall Street Journal has also pointed out that this theory could be used against any manufacturer, not just those that make prescription drugs: “Software, phone, car and medical-device manufacturers — the universe of potential defendants is endless.”
As the Court observed, “Questions currently governed by established defect tests would instead be left to a fact finder’s generalized assessment of reasonableness. This problem is specifically acute in the context of prescription drug development.” The Court also noted that the plaintiffs’ theory “risks circumventing these settled principles” of product liability law.
The Court also acknowledged the perverse incentives this duty would create. Faced with litigation risk at every stage of drug development, manufacturers might decline to even investigate backup or alternative drug candidates. As the Court explained, “manufacturers might forgo early-stage research of backup candidates altogether” — or alternatively, they might “delay commercializing a lead candidate until all backup candidates have been fully explored, slowing patient access while companies search for a hypothetical ‘perfect’ drug.”
That this ruling emerged from California’s Supreme Court is particularly significant, especially given that Los Angeles — the state’s premier trial venue — ranks as the #1 Judicial Hellhole®. California courts have historically been fertile ground for novel litigation theories that later spread nationwide. A ruling embracing a “duty to innovate” in the Golden State would have handed the plaintiffs’ bar a powerful new weapon to deploy in courtrooms across the country. Instead, the Court drew a clear line, deterring other jurisdictions from entertaining similar theories and signaling that even in the nation’s most notorious Judicial Hellhole®, there are limits to how far tort law can be stretched.
